Showiness or efficiency: what to choose?

Authors

  • D.G. Rekalov Zaporizhzhia State Medical University, Ukraine,
  • B.B. Samura Zaporizhzhia State Medical University, Ukraine,
  • R.L. Kulinich Zaporizhzhia State Medical University, Ukraine,
  • M.P. Kras’ko Zaporizhzhya Regional Clinical Hospital, Ukraine,
  • N.I. Kargals’ka Zaporizhzhya Regional Clinical Hospital, Ukraine,
  • V.V. Brylyova Zaporizhzhya Regional Clinical Hospital, Ukraine,

DOI:

https://doi.org/10.14739/2310-1237.2013.2.17363

Keywords:

osteoarthritis, chondroitin sulfate, glucosamine sulfate, NSAIDs

Abstract

BACKGROUND: Osteoarthritis is a leading cause of disability in the world. Current treatment focuses on symptom relief and improving a patient's overall function. Pharmacological treatment’s aim is to correct symptomatic complaints as well as structural problems in osteoarthritis.

Ibuprofen is a non-selective cyclo-oxygenase inhibitor approved for the relief of signs and symptoms of osteoarthritis.

Glucosamine sulfate and chondroitin sulfate have been linked as an optional treatment in osteoarthritis for several years. There is controversy, however, surrounding their use and efficacy. Despite conflicting results on the degree of efficacy, the most current research suggested that glucosamine and chondroitin sulfate have the potential to provide pain-relieving benefits as well as possibly decrease the effects of joint space narrowing.

They are thought to act by affecting cytokine-mediated pathways regulating inflammation, cartilage degradation, and immune responses. Given the results of recent studies, investigators have begun to question whether the popular combination of glucosamine and chondroitin alleviates disease progression or pain in people with mild to moderate knee osteoarthritis. Reasons proposed for the lack of benefit include incorrect dosing, suboptimal compound manufacture, and a lack of complete understanding of when and how to apply the compounds. In addition, adjuvant medications also could augment the therapeutic potential of these agents. Although these agents are considered safe, some uncommon and minor adverse effects have been reported.

OBJECTIVE: The aim of the present study was to examine the effectiveness and safety of combination of ibuprofen, glucosamine sulfate and chondroitin sulfate in patients suffering from knee osteoarthritis. 

METHODS: 80 subjects (32 males and 48 females) were enrolled into the study. 39 patients were treated with combination of glucosamine sulfate, chondroitin sulfate and ibuprofen (first group), and 41 patients were treated with acetaminophen (second group). Clinical outcomes were measured using the knee osteoarthritis measure for symptoms and a study diary-based visual analog scale for pain at baseline and during treatment period.

RESULTS: The results showed that pain was significantly decreased in patients of first group (62,5%). However, it was shown no significant differences in patients of second group.

CONCLUSIONS: It was set that application of  glucosamine sulfate, chondroitin sulfate and ibuprofen in a standard dose does not only allows to obtain a rapid positive dynamics in regarding to a pain syndrome, joint stiffness in this category of patients but also to forecast similar results on subsequent stages. Efficiency of glucosamine sulfate, chondroitin sulfate and ibuprofen combination was set in the patients of senior age-dependent group, and also with high type of safety.

Adverse reactions were similar among treatment groups and serious adverse events were rare for all treatments.

References

Коваленко В.Н. Остеоартроз. Практическое руководство / Коваленко В.Н., Борткевич О.П. – К.: Морион, 2003. – 450 c.

Насонов Е.Л. Нестероидные противовоспалительные препараты: проблемы безопасности лечения / Насонов Е.Л. // Consilium Medicum. – 1999. – Том I, №5. – Режим доступа: http://www.consilium-medicum.com/article/15229

Поворознюк В.В. Остеоартроз: современные принципы лечения // Здоров’я України. – 2003. – №83. – Режим доступу: http://health-ua.com/articles/469.html

Cooper C. Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity / Cooper C., Inskip H., Croft P., et al. // Am J Epidemiol. – 1998. – Vol. 147 (6). – P. 516–522.

Guccione A.A. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study / Guccione A.A., Felson D.T., Anderson J.J., et al. // Am J Public Health. – 1994. – Vol. 84. – P. 351–358.

Hochberg M. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee / Hochberg M., Altman R., Toupine K., et al. // Arthritis Care & Research. – 2012. – Vol. 64. – P. 465–474.

Moore N. The PAIN study (Paracetamol, Aspirin and Ibuprofen New tolerability study): A large-scale randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia / Moore N., Van Ganse E., Le Parc J.-M. et al. // Clin Drug Invest. – 1999. – Vol. 18 (2). – P. 89–98.

Morreale P. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis / Morreale P., Manopulo R., Galati M. et. Al. // J. Rheumatol. – 1996. – Vol. 23 (8). – P. 1385–1391.

Peat G. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care / Peat G., McCarney, Croft P. // Ann Rheum Dis. – 2001. – Vol. 60. – P. 91–97.

Reichenbach S. Meta-analysis: chondroitin for osteoarthritis of the knee or hip / Reichenbach S., Sterchi R., Scherer M., et al. // Ann Intern Med. – 2007. – Vol. 146. – P. 580–590.

Towheed T. Glucosamine therapy for treating osteoarthritis (Review) / Towheed T., Maxwell L., Anastassiades T.P. et al. // The Cochrane Library. – 2009. – Issue 4.

Sawitzke A.D. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT / Sawitzke A.D., Shi H., Clegg D.O., et al. // Ann Rheum Dis. – 2010. – Vol. 69 (8). – P. 1459–1464.

Silverstein F.E. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study / Silverstein F.E., Faich G., Goldstein J.L., et al. // JAMA. – 2000. – Vol. 284 (10). – P. 1247–1255.

Singh J.A. Chondroitin for osteoarthritis / Singh J.A., Wilt T., MacDonald R. // The Cochrane Library. – 2009. – Issue 1.

Wandel S. Effects of glucosamine, chondroitin, or placebo inpatients with osteoarthritis of hip or knee: network meta-analysis / Wandel S., Juni P., Tendal B., et al. // BMJ. – 2010. – Vol. 341. – c4675.

Downloads

Published

2013-10-01

How to Cite

1.
Rekalov D, Samura B, Kulinich R, Kras’ko M, Kargals’ka N, Brylyova V. Showiness or efficiency: what to choose?. Pathologia [Internet]. 2013Oct.1 [cited 2024Nov.2];(2). Available from: http://pat.zsmu.edu.ua/article/view/17363

Issue

No. 2 (2013)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).